Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Unresectable Hepatocellular Carcinoma

NCT07368023 is registered in ClinicalTrials.gov with Ningbo Medical Center Lihuili Hospital as lead sponsor.

NCT NCT07368023
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07368023 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Unresectable Hepatocellular Carcinoma
Lead sponsor
Ningbo Medical Center Lihuili Hospital
Phase
Observational
Overall status
Not yet recruiting
Start date
January 25, 2026
Completion date
May 31, 2026
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, hepatocellular carcinoma non-resectable